StockData
Oruka Therapeutics, Inc. logo

Oruka Therapeutics, Inc. (ORKA) stock

ORKANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$96.32−2.92 (-2.94%)

Close on Nov 17, 2026Market cap $6.38BP/E –Yield –

Oruka Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Oruka Therapeutics's ebitda for the twelve months ending Jun 30, 2024 was -$27.49M. For fiscal 2023 it was -$7.28M. The highest annual figure on record is -$4.28M in fiscal 2012.

Annual ebitda

PeriodPeriod endValueChange
FY2023Dec 31, 2023-$7.28M–
FY2022Dec 31, 2022-$10.58M–
FY2021Dec 31, 2021-$19.32M–
FY2020Dec 31, 2020-$9.76M–
FY2019Dec 31, 2019-$5.80M–
FY2018Dec 31, 2018-$8.10M–
FY2017Dec 31, 2017-$18.69M–
FY2016Dec 31, 2016-$16.59M–
FY2015Dec 31, 2015-$11.44M–
FY2014Dec 31, 2014-$9.68M–
FY2013Dec 31, 2013-$6.91M–
FY2012Dec 31, 2012-$4.28M–
FY2011Dec 31, 2011-$6.76M–
FY2010Dec 31, 2010-$8.84M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2024Jun 30, 2024-$21.49M–
Q1 FY2024Mar 31, 2024-$2.48M–
Q4 FY2023Dec 31, 2023-$1.59M–
Q3 FY2023Sep 30, 2023-$1.93M–
Q2 FY2023Jun 30, 2023-$1.97M–
Q1 FY2023Mar 31, 2023-$1.79M–
Q4 FY2022Dec 31, 2022-$1.54M–
Q3 FY2022Sep 30, 2022-$2.55M–
Q2 FY2022Jun 30, 2022-$3.21M–
Q1 FY2022Mar 31, 2022-$3.27M–
Q4 FY2021Dec 31, 2021-$5.68M–
Q3 FY2021Sep 30, 2021-$4.71M–
Q2 FY2021Jun 30, 2021-$4.83M–
Q1 FY2021Mar 31, 2021-$4.10M–
Q4 FY2020Dec 31, 2020-$5.12M–
Q1 FY2020Mar 31, 2020-$1.34M–
Q4 FY2019Dec 31, 2019-$1.28M–
Q3 FY2019Sep 30, 2019-$1.24M–
Q2 FY2019Jun 30, 2019-$1.50M–
Q1 FY2019Mar 31, 2019-$1.78M–
Q4 FY2018Dec 31, 2018-$1.52M–
Q3 FY2018Sep 30, 2018-$1.66M–
Q2 FY2018Jun 30, 2018-$2.15M–
Q1 FY2018Mar 31, 2018-$2.77M–
Q4 FY2017Dec 31, 2017-$4.29M–
Q3 FY2017Sep 30, 2017-$4.47M–
Q2 FY2017Jun 30, 2017-$5.55M–
Q1 FY2017Mar 31, 2017-$4.37M–
Q4 FY2016Dec 31, 2016-$4.29M–
Q3 FY2016Sep 30, 2016-$4.70M–
Q2 FY2016Jun 30, 2016-$3.94M–

More Oruka Therapeutics figures

See a number that looks wrong?